window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : September 17, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

post-bariatric hypoglycemia

  • Biotech & Pharma Business,Drug Discovery & Development,Pharmaceuticals and therapeutics

    Confo therapeutics nominates SSTR5 agonist antibody CFTX-2034 for post-bariatric hypoglycemia

    Confo Therapeutics has selected CFTX-2034, an SSTR5 agonist antibody, as [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • AstraZeneca advances oral COPD drug into Phase 2b trial
    Categories: Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Fuse Diagnostics raises £1M to scale rapid molecular testing platform
    Categories: Biotech & Pharma Business, Manufacturing & Supply Chain, Medical devices, Research & Development
  • Amyl Therapeutics raises €8.25M to advance pan-amyloid neurodegenerative disease platform
    Categories: Central Nervous System, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top